Goodpasture's syndrome

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

Jump to: navigation, search
Goodpasture's syndrome
Classification and external resources
ICD-10 M31.0 (ILDS M31.010)
ICD-9 446.21
OMIM 233450
DiseasesDB 5363
eMedicine med/923  ped/888
MeSH D019867

WikiDoc Resources for

Goodpasture's syndrome

Articles

Most recent articles on Goodpasture's syndrome

Most cited articles on Goodpasture's syndrome

Review articles on Goodpasture's syndrome

Articles on Goodpasture's syndrome in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Goodpasture's syndrome

Images of Goodpasture's syndrome

Photos of Goodpasture's syndrome

Podcasts & MP3s on Goodpasture's syndrome

Videos on Goodpasture's syndrome

Evidence Based Medicine

Cochrane Collaboration on Goodpasture's syndrome

Bandolier on Goodpasture's syndrome

TRIP on Goodpasture's syndrome

Clinical Trials

Ongoing Trials on Goodpasture's syndrome at Clinical Trials.gov

Trial results on Goodpasture's syndrome

Clinical Trials on Goodpasture's syndrome at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Goodpasture's syndrome

NICE Guidance on Goodpasture's syndrome

NHS PRODIGY Guidance

FDA on Goodpasture's syndrome

CDC on Goodpasture's syndrome

Books

Books on Goodpasture's syndrome

News

Goodpasture's syndrome in the news

Be alerted to news on Goodpasture's syndrome

News trends on Goodpasture's syndrome

Commentary

Blogs on Goodpasture's syndrome

Definitions

Definitions of Goodpasture's syndrome

Patient Resources / Community

Patient resources on Goodpasture's syndrome

Discussion groups on Goodpasture's syndrome

Patient Handouts on Goodpasture's syndrome

Directions to Hospitals Treating Goodpasture's syndrome

Risk calculators and risk factors for Goodpasture's syndrome

Healthcare Provider Resources

Symptoms of Goodpasture's syndrome

Causes & Risk Factors for Goodpasture's syndrome

Diagnostic studies for Goodpasture's syndrome

Treatment of Goodpasture's syndrome

Continuing Medical Education (CME)

CME Programs on Goodpasture's syndrome

International

Goodpasture's syndrome en Espanol

Goodpasture's syndrome en Francais

Businness

Goodpasture's syndrome in the Marketplace

Patents on Goodpasture's syndrome

Experimental / Informatics

List of terms related to Goodpasture's syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884

Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2] Phone:617-525-7431

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [3] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Goodpasture’s syndrome (also known as Goodpasture’s disease and anti-glomerular basement membrane disease) is a rare condition characterised by rapid destruction of the kidneys and hemorrhaging of the lungs.

Although many diseases can present with these symptoms, the name Goodpasture’s syndrome is usually reserved for the autoimmune disease produced when the patient’s immune system attacks cells presenting the Goodpasture antigen, which are found in the kidney and lung, causing damage to these organs.

Signs and symptoms

Most patients present with both lung and kidney disease, however, some patients present with one of these diseases alone. The first lung symptoms usually develop days to months before kidney damage is evident. There is an increased incidence of syndactly.

Lung disease

Lung damage may cause nothing more serious than a dry cough and minor breathlessness and such mild symptoms may last for many years before more severe ones develop. At its most serious, however, lung damage may cause severe impairment of oxygenation so that intensive care is required. Deterioration between the two extremes may occur very rapidly, often at the same time as rapid deterioration in the kidney. The patient often does not seek medical attention until he or she begins coughing up blood (hemoptysis). The patient may be anemic due to loss of blood through lung haemorrhaging over a long period. In Goodpasture’s syndrome, unlike many other conditions that cause similar symptoms, lung hemorrhaging most often occurs in smokers and those with damage from lung infection or exposure to fumes.

Kidney disease

The kidney disease mostly affects the glomeruli causing a form of nephritis. It is usually not detected until a rapid advance of the disease occurs so that kidney function can be completely lost in a matter of days, a condition known as rapidly progressive glomerulonephritis, or RPGN. Blood leaks into the urine causing hematuria, the volume urinated decreases and urea and other products usually excreted by the kidney are retained and build up in the blood. This is acute renal failure. Renal failure does not cause symptoms until more than 80% of kidney function has been lost. Symptoms include loss of appetite and sickness at first and then, when the damage is more advanced, breathlessness, high blood pressure and edema (swelling caused by fluid retention). The kidney involvement usually presents as nephritic syndrome, i.e. hematuria, a reduced glomerular filtration rate, and high blood pressure. This is in contrast to nephrotic syndrome, a more rare outcome of Goodpasture's, characterized by an abnormally large amount protein in the urine (proteinuria), coupled with severe edema.

Diagnosis

Because of the vagueness of early symptoms and rapid progression of the disease, diagnosis is often not reached until very late in the course of the disease. Kidney biopsy is often the fastest way to secure the diagnosis and gain information about the extent of the disease and likely effect of treatment. Tests for anti-GBM antibodies may also be useful, combined with tests for antibodies to neutrophil cytoplasmic antigens, which are also directed against the patient’s own proteins.

Pathology

Goodpasture Disease
Goodpasture Disease[1]


Pathophysiology

As with many autoimmune conditions, the precise cause of Goodpasture’s Syndrome is not yet known. It is believed to be a type II hypersensitivity reaction to Goodpasture’s antigens on the cells of the glomeruli of the kidneys and the pulmonary alveoli, specifically the basement membrane's (including a-3 chain of type IV collagen), whereby the immune system wrongly recognizes these cells as foreign and attacks and destroys them, as it would an invading pathogen.

Treatment

Like many autoimmune diseases, Goodpasture’s syndrome responds well to treatment with corticosteroids and immunosuppressants. These drugs dampen the body's normal immune response. A serious side effect of this is that the patient may become more susceptible to infections. The concentration of anti-GBM antibodies in the blood may be reduced by apheresis to remove blood plasma and its replacement with an isotonic salt and protein solution. This course of treatment usually lasts between three and six months.

Antibiotic treatment of lung infection and stopping smoking may also help to reduce lung haemorrhaging.

However, none of these can reverse permanent kidney damage and so for patients who have suffered this, renal transplant once the disease has subsided may be the only option.

Epidemiology

Goodpasture’s syndrome is rare. In European populations between half and one case presents per million people per year. It is rarer than this in non-European populations. While cases have occurred in patients between the ages of 4 and 80, it is most common between ages 18 and 30 and again between 50 and 65. Males are six times more affected than females.

Prognosis

In the 1970s, Goodpasture’s syndrome was most often fatal, but due to advances in diagnosis and treatment deaths are less common now. Death from lung hemorrhage may occur before the diagnosis has been made or in the initial stages of treatment before it has been properly controlled. With treatment, however, the patient can usually recover completely from lung damage. Kidneys, though, are less able to repair themselves and patients with kidney damage must often resort of a life on dialysis or kidney transplantation. Even with the best management there is still a significant mortality from renal failure, particularly if the patient is otherwise in poor health. It must also be remembered that the immunosuppressive treatment many patients are put on increases their risk of infection with a number of serious or fatal diseases.

See also

HLA-DR#DR2

References

External links

GBM antibodies: immunofluorescence image

de:Goodpasture-Syndromja:グッドパスチャー症候群fi:Goodpasturen oireyhtymä

sv:Goodpastures syndrom

WikiDoc Help Menu

Quick Start..

Editing basics

Advanced editing

Communicating your edits

Help Videos You Can Watch


Acknowledgement and Attribution Regarding Sources of Content

Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

Personal tools
related articles
viewed previously [ + ]
In other languages